ProQR Announces Annual Meeting of Shareholders

Rhea-AI Summary

ProQR Therapeutics N.V. (NASDAQ: PRQR) announced its Annual General Meeting of Shareholders will be held on June 23, 2020, at 15:00 CET via videoconference. Shareholders can access all relevant documents, including the notice and agenda, on ProQR’s website and the SEC’s website. ProQR is focused on developing transformative RNA therapies for severe genetic rare diseases, leveraging its proprietary RNA repair platform technologies since 2012.

Positive

• ProQR is dedicated to developing RNA therapies for severe genetic diseases.
• The company utilizes proprietary RNA repair platform technologies.
• ProQR has been operational since 2012, indicating stability in its business model.

Negative

• None.

Leiden, Netherlands & Cambridge, Mass., May 25, 2020 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transformative RNA therapies for severe genetic rare diseases, today announced that the Annual General Meeting of Shareholders will take place on Tuesday, June 23, 2020 at 15:00 CET, via videoconference.

All relevant documents and information for the meeting, including the notice and agenda, are or will be made available in the “Investors” section of ProQR’s website (www.proqr.com) under “Financial Information”. The documents will also be made available on the SEC’s website at www.sec.gov.  Shareholders that wish to attend the videoconference should register for attendance as described in the notice and agenda, after which they will receive login details for the videoconference.

About ProQR

ProQR Therapeutics is dedicated to changing lives through the creation of transformative RNA therapies for the treatment of severe genetic rare diseases such as Leber congenital amaurosis 10, Usher syndrome and autosomal dominant retinitis pigmentosa. Based on our unique proprietary RNA repair platform technologies we are growing our pipeline with patients and loved ones in mind.
*Since 2012*

ProQR Therapeutics N.V.

Investor Contact:
Sarah Kiely
ProQR Therapeutics N.V.
T: +1 617 599 6228
skiely@proqr.com
or
Hans Vitzthum
LifeSci Advisors
T: +1 617 535 7743
hans@lifesciadvisors.com  

Media Contact:
Sara Zelkovic
LifeSci Public Relations
T: +1 646 876 4933
sara@lifescipublicrelations.com

FAQ

When is the ProQR Therapeutics Annual General Meeting scheduled?

The ProQR Therapeutics Annual General Meeting is scheduled for June 23, 2020.

How can shareholders attend the ProQR meeting?

Shareholders can attend the ProQR meeting via videoconference by registering for attendance.

What is the focus of ProQR Therapeutics?

ProQR Therapeutics focuses on creating transformative RNA therapies for severe genetic rare diseases.

Where can I find documents for the ProQR Annual General Meeting?

Relevant documents for the ProQR Annual General Meeting are available on their website and the SEC's website.

What time will the ProQR Annual General Meeting take place?

The ProQR Annual General Meeting will take place at 15:00 CET.